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Abstract
The insulin-like growth factor (IGF) signal transduction pathway appears to play a key role in the
development and proliferation of the Ewing sarcoma family of tumors. Integration of anti-IGF-1
receptor therapy into the standard treatment for these patients is a novel approach that will likely be
incorporated into future treatment to determine whether such agents will improve the outcome for
patients with this malignancy.
Introduction and context
The Ewing sarcoma family of tumors, including Ewing
sarcoma and the more differentiated counterpart, primi-
tive neuroectodermal tumor, are the second most
common primary malignancies of bone in childhood
and adolescence [1] but can also occur in the soft tissues.
These tumors are characterized by local destruction with
the potential for distant metastatic spread. Treatment is
multimodal and includes chemotherapy, surgery, and/or
radiation therapy. Systemic chemotherapy is aimed at
treating known or micrometastatic disease as well as
improving local control of the cancer.
Historically, multiagent chemotherapy has been the
standard of care for these patients. The Intergroup
Ewing sarcoma study (INT-0091) demonstrated that a
regimen of alternating cycles of vincristine-doxorubicin-
cyclophosphamide and ifosfamide-etoposide was sup-
erior to vincristine-doxorubicin-cyclophosphamide
alone, leading to a 5-year event-free survival of 69%
versus 54% in the standard arm [2]. More recently, a
randomized trial evaluated dose intensification by inter-
val compression (administering cycles every 2 weeks) and
found that approach to be superior, with a 4-year event-
freesurvival of76%inthe dose-densearmcomparedwith
65%inthestandard3-weekchemotherapyarm[3].Thisis
now considered by pediatric oncologists to be the
standard chemotherapy regimen for patients with Ewing
sarcoma,although ithas not beenadequately evaluated in
patients older than 18.
Although there have been improvements in the outcome
for patients with localized disease, the outcome for
patients with metastatic disease and for those who
relapse is poor, with survival rates of 20% for those with
metastases [2,4] and 10-20% following a recurrence [5].
Therefore, in addition to standard chemotherapeutics,
future clinical trials will need to incorporate novel
biologic agents in an effort to achieve further survival
improvements.
The insulin-like growth factor pathway and cancer
The insulin-like growth factor (IGF) system has two
principal ligands: IGF-1 and IGF-2. These ligands
mediate their stimulatory effects via the IGF-1 receptor
(IGF-1R), a transmembrane receptor tyrosine kinase [6].
Under normal physiologic circumstances, IGF-1 and
IGF-2 are stimulated by growth hormone and function in
a negative feedback loop to control growth hormone
release. The insulin growth factor-binding proteins
(IGFBPs) regulate the available free IGF proteins avail-
able for IGF-1R activation [7-9]. Upon ligand binding,
autophosphorylation of the IGF-1R tyrosine kinase
initiates activation of the mitogen-activated protein
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leading to proliferation, survival [10-13], and enhanced
angiogenesis via downstream induction of vascular
endothelial growth factor [14]. The IGF-2 receptor is
a monomeric transmembrane protein with no kinase
activity and has not been shown to play a role in the
development of Ewing sarcoma [15]. Its role in binding
IGF-2 has yet to be elucidated.
The IGF pathway is known to be a critical component of
the endocrine system. Stimulation has effects on linear
growth and bone formation. The pathway also has a role
in promoting neuronal survival, myelination, and
postnatal mammary development and lactation. In
addition, metabolic pathways use the IGF system to
help integrate signals from nutrition and stress in order
to shift appropriately between anabolic and catabolic
states [6].
High circulating levels of IGF-1 have been associated
with the risk of developing prostate, breast, or colorectal
cancer [16,17]. In addition, overexpression of IGF-1 has
been shown to promote neoplastic transformation [18].
The IGF-1R is expressed at high levels in a wide variety of
tumors [19,20]. In addition, IGF-1R expression is known
to be necessary for cellular transformation and for signal
transduction pathways stimulated by the IGF-1R to
enhance tumor cell growth and proliferation [21,22].
Furthermore, IGF-1R gene expression is regulated by a
number of tumor suppressors, including WT1, BRCA1,
and p53 [20]. There are also data to suggest that signaling
through the IGF-1R enhances resistance to cytotoxic
chemotherapy [23]. Therefore, inhibition of the IGF-1R
is a potentially important therapeutic target against
a variety of tumors.
Recent advances
Targeting insulin-like growth factor 1 receptor
in Ewing sarcoma
The IGF signaling pathway and, in particular, the IGF-1R
play a major role in the development and proliferation
of Ewing sarcoma. Early studies documented the major
autocrine role of the IGF-1 and IGF-1R pathways in
Ewing sarcoma [24,25], and expression of IGF-1R has
been shown to be a requirement for EWS/FLI-1
transformation in fibroblasts [26]. A variety of app-
roaches in vitro and in animal models have been
undertaken to disrupt the IGF-1R signaling pathway,
including the development of small-molecule tyrosine
kinase inhibitors (TKIs) and anti-IGF-1R antibodies. In
preclinical testing, there was an initial difficulty in
obtaining specific small-molecule kinase inhibitors of
the IGF-1R due to a very-high-sequence homology with
kinase and ATP-binding domains of the insulin receptor
[27]. Thus, major progress was initially slowed due to
toxicity concerns. After initial attempts, the TKI NVP-
AEW541 was shown to have a 27-fold increased
selectivity for the IGF-1R over the insulin receptor [28].
This small-molecule TKI has shown promise in
preclinical models, where inhibition of migration,
metastasis, and angiogenesis was seen in vitro and a
significant reduction in tumor growth was seen in
xenograft models [29]. Further elucidation of the
metabolic alterations related to the use of TKIs will be
necessary prior to entry into clinical trials.
More recently, targeted antibodies have been shown
not only to disrupt ligand-receptor binding, but also to
decrease surface IGF-1R expression by internalization
and degradation of the antibody-bound receptor
[30,31]. Human monoclonal anti-IGF-1R antibodies
have been produced by many pharmaceutical compa-
nies: IMC-A12 (ImClone Systems, New York, NY,
U S A ) ,A M G4 7 9( A m g e n ,T h o u s a n dO a k s ,C A ,U S A ) ,
R1507 (Roche, Basel, Switzerland), CP-751,871 (Pfizer
Inc, New York, NY, USA), SCH717454 (Schering-
Plough Corporation, Kenilworth, NJ, USA), MK-0646
(Merck), and AVE1642 (ImmunoGen, Inc, Waltham,
MA, USA/Sanofi-Aventis, Paris, France). These antibo-
dies have been tested in preclinical settings and
ongoing early-phase adult studies [30,32-36]. How-
ever, few of these have been tested in patients with
Ewing sarcoma.
The SCH717454 IGF-1R antibody was tested against
a panel of pediatric tumors by the Pediatric Preclinical
Testing Program, a comprehensive program to system-
atically evaluate new agents against childhood solid
tumor and leukemia models. Intermediate or high
activity was demonstrated in two of five Ewing sarcoma
xenografts, including one complete response [36]. In
addition, the IMC-A12 antibody is currently under
investigation in a phase II Children’s Oncology Group
(COG) trial, with a stratum available for patients with
Ewing sarcoma. Through the Sarcoma Alliance for
Research through Collaboration (SARC), the R1507
antibody has been tested in two phase I studies in adults
[37,38]. The first study assessed the administration of the
antibody on a 3-week basis and was well tolerated,
without any dose-limiting toxicity or serious adverse
events; 11 of 26 patients were found to have stable
disease, although none had Ewing sarcoma [38]. In the
second study, four of eight heavily pretreated patients
with Ewing sarcoma demonstrated stable disease, with
two of eight patients demonstrating durable partial
responses [37].
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Human monoclonal antibody therapy directed against
the IGF-1R holds great promise for improving the
prognosis for children, adolescents, and adults with
Ewing sarcoma. The recent data demonstrating responses
in heavily pretreated patients with refractory Ewing
sarcoma bring a wave of excitement to move these
therapies to the forefront. Clinical trials are under way
to assess the feasibility and efficacy of combining anti-
IGF-1R therapy with multiagent chemotherapy. Over the
next 5 years, feasibility testing will be completed, and if
successful, phase III studies will assess whether the
addition of these new agents will result in therapeutic
improvements.
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